Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

DaShenLin Pharmaceutical Group Co., Ltd. (603233.SS)

18.92
+0.34
+(1.83%)
At close: April 30 at 3:00:03 PM GMT+8
Loading Chart for 603233.SS
  • Previous Close 18.58
  • Open 18.50
  • Bid 18.90 x --
  • Ask 18.92 x --
  • Day's Range 18.28 - 19.00
  • 52 Week Range 11.92 - 23.26
  • Volume 11,165,367
  • Avg. Volume 8,506,532
  • Market Cap (intraday) 21.547B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 22.00
  • EPS (TTM) 0.86
  • Earnings Date --
  • Forward Dividend & Yield 0.62 (3.28%)
  • Ex-Dividend Date Oct 23, 2024
  • 1y Target Est --

DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. It provides Chinese and western patent medicines, ginseng tonic medicinal materials and Chinese herbal pieces, health care products, medical equipment, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.

www.dslyy.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603233.SS

View More

Performance Overview: 603233.SS

Trailing total returns as of 4/30/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603233.SS
25.63%
SSE Composite Index (000001.SS)
2.17%

1-Year Return

603233.SS
9.53%
SSE Composite Index (000001.SS)
5.61%

3-Year Return

603233.SS
11.98%
SSE Composite Index (000001.SS)
7.61%

5-Year Return

603233.SS
33.87%
SSE Composite Index (000001.SS)
14.65%

Compare To: 603233.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603233.SS

View More

Valuation Measures

As of 4/30/2025
  • Market Cap

    21.55B

  • Enterprise Value

    21.64B

  • Trailing P/E

    22.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.80

  • Price/Book (mrq)

    2.93

  • Enterprise Value/Revenue

    0.81

  • Enterprise Value/EBITDA

    14.51

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.45%

  • Return on Assets (ttm)

    3.99%

  • Return on Equity (ttm)

    12.20%

  • Revenue (ttm)

    26.5B

  • Net Income Avi to Common (ttm)

    914.75M

  • Diluted EPS (ttm)

    0.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.74B

  • Total Debt/Equity (mrq)

    79.16%

  • Levered Free Cash Flow (ttm)

    2.47B

Research Analysis: 603233.SS

View More

People Also Watch